Sotelo, Marta and Peláez, Mireia and Basterretxea, Laura and Varga, Estrella and Sánchez-Escribano, Ricardo and Pujol Obis, Eduardo and Santander, Carmen and Martínez Kareaga, Mireia and Arruti Ibarbia, Mikel and Rodríguez Ledesma, Inmaculada and Álvarez Fernández, Carlos and Piedra, Pablo and Calderero Aragón, Verónica and Lainez, Nuria and Verdún Aguilar, Juan Antonio and Gil Arnáiz, Irene and Fernández, Ricardo and Mazas Pérez-Oleaga, Cristina and Duran, Ignacio UNSPECIFIED, mireia.pelaez@uneatlantico.es, UNSPECIFIED, UNSPECIFIED, UNSPECIFIED, UNSPECIFIED, UNSPECIFIED, UNSPECIFIED, UNSPECIFIED, UNSPECIFIED, UNSPECIFIED, UNSPECIFIED, UNSPECIFIED, UNSPECIFIED, UNSPECIFIED, UNSPECIFIED, UNSPECIFIED, cristina.mazas@uneatlantico.es, UNSPECIFIED (2025) Avelumab maintenance in advanced urothelial carcinoma: real-world data from Northern Spain (AVEBLADDER study). Clinical and Translational Oncology. ISSN 1699-3055
![[img]](/style/images/fileicons/text.png) |
Text
s12094-025-03950-w.pdf Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) |
Abstract
Background Before the incorporation of enfortumab vedotin with pembrolizumab, the standard of care for patients with locally advanced or metastatic urothelial carcinoma who do not progress after platinum-based chemotherapy was avelumab maintenance therapy, as demonstrated by the JAVELIN 100 trial. However, real-world European data remain scarce. Patients and Methods AVEBLADDER is a retrospective study conducted at 14 hospitals in Northern Spain, including patients with locally advanced or metastatic urothelial carcinoma diagnosed between January 2021 and June 2023. Outcomes of overall survival (OS) and progression-free survival (PFS) were analyzed for patients treated with platinum-based chemotherapy, with and without subsequent avelumab maintenance therapy. non-avelumab patients. Median PFS was 11.33 months (95% CI: 10–13.6) with avelumab and 6.43 months (95% CI: 6–7.6) without. One-year OS probabilities were 81.6% vs. 45.6% (p < 0.001) in the avelumab and non-avelumab groups, respectively. No unexpected toxicities were reported. Conclusions Despite proven survival benefits, avelumab uptake in real-world practice is limited by barriers like access, reimbursement, and awareness. These findings align with JAVELIN 100 and underscore the need for further real-world studies to address treatment disparities.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Avelumab; Locally advanced/metastatic urothelial cancer; Treatment outcomes; Real-world data |
| Subjects: | Subjects > Biomedicine |
| Divisions: | Europe University of Atlantic > Research > Scientific Production |
| Depositing User: | Sr Bibliotecario |
| Date Deposited: | 24 Jun 2025 08:16 |
| Last Modified: | 24 Jun 2025 08:16 |
| URI: | http://repositorio.funiber.org/id/eprint/17813 |
Actions (login required)
 |
View Item |
